Bristol Myers Squibb Company $BMY Stock: Arnhold LLC Decreases Position

Key Points

• Arnhold LLC reduced its Bristol Myers Squibb stake by 5.2% in the third quarter, selling 22,714 shares and retaining 417,229 shares valued at approximately $26.0 million.
• Institutional ownership remains high at 76.41%, with major investors including BlackRock, Lazard Asset Management and Envestnet increasing their positions during recent quarters.
• BMY trades near $61.56 with a consensus analyst rating of “Hold” and a $65.50 price target. Investors are balancing promising oncology-trial results and a 4.1% dividend yield against patent-expiration risks and potential declines in legacy-drug revenue.

Arnhold LLC cut its stake in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 5.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 417,229 shares of the biopharmaceutical company's stock after selling 22,714 shares during the period. Bristol Myers Squibb accounts for about 1.9% of Arnhold LLC's portfolio, making the stock its 15th biggest position. Arnhold LLC's holdings in Bristol Myers Squibb were worth $26,035,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also modified their holdings of the company. Lazard Asset Management LLC lifted its position in Bristol Myers Squibb by 23.7% in the first quarter. Lazard Asset Management LLC now owns 1,924,036 shares of the biopharmaceutical company's stock worth $116,693,000 after buying an additional 368,193 shares during the last quarter. Callan Family Office LLC purchased a new position in Bristol Myers Squibb during the second quarter worth $3,575,000. BlackRock Inc. boosted its stake in Bristol Myers Squibb by 5.1% during the second quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company's stock worth $10,393,783,000 after buying an additional 8,702,106 shares during the period. Saudi Central Bank increased its position in Bristol Myers Squibb by 90.2% during the second quarter. Saudi Central Bank now owns 142,922 shares of the biopharmaceutical company's stock valued at $8,235,000 after acquiring an additional 67,780 shares during the last quarter. Finally, Envestnet Asset Management Inc. increased its position in Bristol Myers Squibb by 17.4% during the second quarter. Envestnet Asset Management Inc. now owns 2,142,754 shares of the biopharmaceutical company's stock valued at $123,465,000 after acquiring an additional 317,360 shares during the last quarter. 76.41% of the stock is owned by institutional investors.

Bristol Myers Squibb News Summary

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Promising lung-cancer results: Iza-bren doubled median progression-free survival versus chemotherapy in previously treated EGFR-mutated non-small-cell lung cancer in the Phase 3 PANKU-Lung01 study. The results strengthen the potential of BMY’s pipeline to offset declining legacy-drug revenue. Iza-bren lung-cancer Phase 3 results
• Positive Sentiment: Additional oncology momentum: A Phase 3 breast-cancer study reportedly showed Iza-bren reduced disease-progression risk by as much as 38%, while a Phase 2 trial of BMY and BioNTech’s pumitamig plus docetaxel produced a 36.7% response rate in advanced non-small-cell lung cancer. These programs could broaden BMY’s growth-drug portfolio. BMY cancer breakthrough Pumitamig Phase 2 data
• Positive Sentiment: Analyst remains bullish: Piper Sandler maintained an “overweight” rating and still sees substantial potential upside, despite reducing its price target from $82 to $78. Piper Sandler BMY rating
• Neutral Sentiment: Q3 earnings focus: Investors are weighing growth from newer medicines and improved Eliquis guidance against declines in BMY’s legacy portfolio ahead of quarterly results. Analysts are also monitoring revenue, margins and other operating metrics. BMY Q3 earnings outlook
• Negative Sentiment: Patent-cliff risk persists: Investors remain concerned that patent expirations for two blockbuster drugs could create a significant revenue gap before new medicines fully mature, despite BMY’s low valuation and dividend appeal. BMY patent-cliff analysis
• Negative Sentiment: Cautious earnings sentiment: Erste Group issued a pessimistic earnings outlook, adding to broader sell-side caution around BMY’s growth rate and post-patent-cliff prospects.

Analysts Set New Price Targets

BMY has been the topic of several recent analyst reports. Leerink Partners downgraded shares of Bristol Myers Squibb from an "outperform" rating to a "market perform" rating and reduced their target price for the company from $73.00 to $59.00 in a research note on Monday, October 5th. William Blair reaffirmed a "market perform" rating on shares of Bristol Myers Squibb in a research note on Monday, October 12th. TD Cowen began coverage on shares of Bristol Myers Squibb in a report on Wednesday, August 5th. They set a "buy" rating on the stock. Weiss Ratings raised shares of Bristol Myers Squibb from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Tuesday, August 18th. Finally, Zacks Research downgraded shares of Bristol Myers Squibb from a "strong-buy" rating to a "hold" rating in a research note on Thursday, October 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, sixteen have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $65.50.

Insider Activity at Bristol Myers Squibb

In other news, SVP Phil M. Holzer sold 500 shares of the firm's stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total transaction of $33,750.00. Following the transaction, the senior vice president directly owned 16,862 shares of the company's stock, valued at approximately $1,138,185. This trade represents a 2.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 0.05% of the company's stock.

Bristol Myers Squibb Stock Up 0.1%

Shares of BMY opened at $61.56 on Tuesday. The firm has a fifty day moving average price of $63.20 and a 200-day moving average price of $59.79. The company has a current ratio of 1.53, a quick ratio of 1.38 and a debt-to-equity ratio of 1.89. The firm has a market capitalization of $125.75 billion, a P/E ratio of 9.44, a P/E/G ratio of 0.31 and a beta of 0.19. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $68.64.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.60 by $0.44. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The company had revenue of $12.97 billion for the quarter, compared to the consensus estimate of $11.74 billion. During the same quarter last year, the firm posted $1.46 EPS. The firm's revenue was up 5.7% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Equities research analysts expect that Bristol Myers Squibb Company will post 6.51 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, November 2nd. Shareholders of record on Friday, October 2nd will be paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 4.1%. The ex-dividend date is Friday, October 2nd. Bristol Myers Squibb's dividend payout ratio is currently 55.51%.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb NYSE: BMY is a global biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases. Its research and development activities span oncology, hematology, immunology, cardiovascular disease, neuroscience and other specialty areas.

The company's portfolio includes oncology medicines such as Opdivo, Yervoy, Abraxane, Sprycel and Pomalyst, as well as Eliquis, an anticoagulant developed in partnership with Pfizer. Bristol Myers Squibb also markets immunology and neuroscience products, including Orencia and Sotyktu, and continues to invest in therapies based on biologics, cell therapy and other advanced treatment approaches.

Bristol Myers Squibb traces its roots to pharmaceutical businesses founded by Bristol-Myers in 1881 and E.R.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.